Intravenous Gammaglobulin for Sickle Cell Pain Crises
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01757418|
Recruitment Status : Recruiting
First Posted : December 31, 2012
Last Update Posted : June 11, 2021
The purpose of this study is to determine whether intravenous immune globulin is safe and effective in the acute treatment of pain crises in sickle cell disease.
Funding Source: Food and Drug Administration (FDA), Office of Orphan Products Development (OOPD)
|Condition or disease||Intervention/treatment||Phase|
|Sickle Cell Disease Pain||Drug: Immune Globulin Intravenous Other: Normal saline||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||94 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain|
|Study Start Date :||November 2008|
|Estimated Primary Completion Date :||September 2022|
|Estimated Study Completion Date :||July 2023|
Experimental: Immune Globulin Intravenous
IVIG used in the trial is the GAMUNEX brand, at doses up through 800 mg/kg in Phase 1 and at 400mg/kg in Phase 2.
Drug: Immune Globulin Intravenous
A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.
Other Name: GAMUNEX (Talecris Biotherapeutics)
Placebo Comparator: Normal saline
An equivalent volume (weight-based)of normal saline
Other: Normal saline
A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.
Other Name: Placebo
- Length of vaso-occlusive crisis [ Time Frame: Number of days from time of presentation to emergency room to end of crisis, average 4 days and maximum 30 days ]Length of vaso-occlusive crisis as measured from the time of presentation to the emergency room to end of VOC defined as 12 hours from the last dose of parenteral opioid analgesia for the treatment of VOC prior to hospital discharge.
- Total opioid use in equivalent of mg of IV morphine [ Time Frame: From study drug infusion to end of crisis, average 4 days and maximum 30 days ]End of VOC end of VOC defined as 12 hours from the last dose of parenteral opioid analgesia for the treatment of VOC prior to hospital discharge
- Time to end of vaso-occlusive crisis [ Time Frame: Number of days from start of study drug infusion to end of crisis, average 4 days and maximum 30 days ]Time to end of vaso-occlusive crisis as measured from start of study drug infusion to end of VOC end of VOC defined as 12 hours from the last dose of parenteral opioid analgesia for the treatment of VOC prior to hospital discharge
- In vitro adhesion assays [ Time Frame: Pre and 24 hours post study drug ]Activated Mac-1, Aged neutrophils
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01757418
|Contact: Deepa G Manwani, M.Demail@example.com|
|Contact: Karen Irelandfirstname.lastname@example.org|
|United States, New York|
|Montefiore Medical Center||Recruiting|
|Bronx, New York, United States, 10467|
|Contact: Deepa G Manwani, MD 718-741-2342 email@example.com|
|Principal Investigator: Deepa G Manwani, MD|
|Principal Investigator:||Deepa G Manwani, M.D||Albert Einstein College of Medicine|